Pharnext Shares Top-Line Results from Pivotal Phase 3 Studies of PXT3003; More to Come
News
Pharnext recently provided an update from its ongoing Phase 3 clinical trials evaluating PXT3003 for treating Charcot-Marie-Tooth disease type 1A (CMT1A) in adults, and also announced that some top-line results are ... Read more